The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases

BACKGROUND/AIM: Ruxolitinib, a JAK/STAT signaling pathway inhibitor targeted drug, has been approved for the controlling of disease symptoms and splenomegaly in patients with myeloproliferative neoplastic diseases. Recently, it has been proposed that ruxolitinib-induced JAK/STAT pathway inhibition i...

Descripción completa

Detalles Bibliográficos
Autores principales: TÜRK, Can, OKAY, Müfide, TÜRK, Seyhan, TEMİRCİ, Elif Sena, JAVAD, Osama, AKSU, Salih, SAYINALP, Nilgün, HAZNEDAROĞLU, İbrahim Celalettin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018380/
https://www.ncbi.nlm.nih.gov/pubmed/30997981
http://dx.doi.org/10.3906/sag-1807-152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018380/
https://www.ncbi.nlm.nih.gov/pubmed/30997981
http://dx.doi.org/10.3906/sag-1807-152

Ejemplares similares